Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Kidney Transplantation | Case report

Primary hyperoxaluria diagnosed after kidney transplantation failure: lesson from 3 case reports and literature review

Authors: Ruiming Cai, Minzhuang Lin, Zhiyong Chen, Yongtong Lai, Xianen Huang, Guozhi Zhao, Xuekun Guo, Zhongtang Xiong, Juan Chen, Hui Chen, Qingping Jiang, Shaoyan Liu, Yuexin Yang, Weixiang Liang, Minhui Zou, Tao Liu, Wenfang Chen, Hongzhou Liu, Juan Peng

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Primary hyperoxaluria (PH) is a rare inborn disorder of the metabolism of glyoxylate, which causes the hallmark production oxalate and forms insoluble calcium oxalate crystals that accumulate in the kidney and other organs. Since the manifestation of PH varies from recurrent nephrolithiasis, nephrocalcinosis, and end-stage renal disease with age at onset of symptoms ranging from infancy to the sixth decade, the disease remains undiagnosed until after kidney transplantation in some cases.

Case presentation

Herein, we report 3 cases of PH diagnosed after kidney transplantation failure, providing the comprehensive clinical course, the ultrasonic image of renal graft and pathologic image of the biopsy, highlighting the relevance of biopsy findings and the results of molecular genetic testing. We also focus on the treatment and the unfavorable outcome of the patients. Meanwhile, we review the literature and show the additional 10 reported cases of PH diagnosed after kidney transplantation. Additionally, we discuss the progressive molecular understanding of the mechanisms involved in PH and molecular therapy.

Conclusions

Overall, the necessity of preoperative screening of PH in all patients even with a minor history of nephrolithiasis and the importance of proper treatment are the lessons we learn from the 3 cases, which prompt us to avoid tragedies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Milliner DS, Harris PC, Cogal AG, Lieske JC. Primary Hyperoxaluria type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington; 1993-2018. Initial Posting: June 19, 2002; Last Update: November 30, 2017. Milliner DS, Harris PC, Cogal AG, Lieske JC. Primary Hyperoxaluria type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington; 1993-2018. Initial Posting: June 19, 2002; Last Update: November 30, 2017.
2.
go back to reference Rumsby G, Hulton SA. Primary Hyperoxaluria type 2. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington; 1993-2018. Initial Posting: December 2, 2008; Last Update: December 21, 2017. Rumsby G, Hulton SA. Primary Hyperoxaluria type 2. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington; 1993-2018. Initial Posting: December 2, 2008; Last Update: December 21, 2017.
3.
go back to reference Milliner DS, Harris PC, Lieske JC. Primary Hyperoxaluria type 3. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington; 1993-2018. Initial Posting: September 24, 2015. Milliner DS, Harris PC, Lieske JC. Primary Hyperoxaluria type 3. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington; 1993-2018. Initial Posting: September 24, 2015.
4.
go back to reference Hopp K, Cogal AG, Bergstralh EJ. Et al; on behalf of the rare kidney stone consortium. Phenotype-genotype correlations and estimated carrier frequencies of primary Hyperoxaluria. J Am Soc Nephrol. 2015;26(10):2559–70.CrossRef Hopp K, Cogal AG, Bergstralh EJ. Et al; on behalf of the rare kidney stone consortium. Phenotype-genotype correlations and estimated carrier frequencies of primary Hyperoxaluria. J Am Soc Nephrol. 2015;26(10):2559–70.CrossRef
5.
go back to reference Lorenzo V, Torres A, Salido E. Primary hyperoxaluria. Nefrologia. 2014;34(3):398–412.PubMed Lorenzo V, Torres A, Salido E. Primary hyperoxaluria. Nefrologia. 2014;34(3):398–412.PubMed
6.
go back to reference Bollée G, Cochat P, Daudon M. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria. Can J Kidney Health Dis. 2015;2:31.CrossRef Bollée G, Cochat P, Daudon M. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria. Can J Kidney Health Dis. 2015;2:31.CrossRef
7.
go back to reference Riksen NP, Timmers HJ, Assmann KJ, et al. Renal graft failure due to type 1 primary hyperoxaluria. Neth J Med. 2002;60(10):407–10.PubMed Riksen NP, Timmers HJ, Assmann KJ, et al. Renal graft failure due to type 1 primary hyperoxaluria. Neth J Med. 2002;60(10):407–10.PubMed
8.
go back to reference Kim HH, Koh HI, Ku BI, et al. Late-onset primary hyperoxaluria diagnosed after renal transplantation presented with early recurrence of disease. Nephrol Dial Transplant. 2005;20(8):1738–40.CrossRef Kim HH, Koh HI, Ku BI, et al. Late-onset primary hyperoxaluria diagnosed after renal transplantation presented with early recurrence of disease. Nephrol Dial Transplant. 2005;20(8):1738–40.CrossRef
9.
go back to reference Madiwale C, Murlidharan P, Hase NK. Recurrence of primary hyperoxaluria: an avoidable catastrophe following kidney transplant. J Postgrad Med. 2008;54(3):206–8.CrossRef Madiwale C, Murlidharan P, Hase NK. Recurrence of primary hyperoxaluria: an avoidable catastrophe following kidney transplant. J Postgrad Med. 2008;54(3):206–8.CrossRef
10.
go back to reference Celik G, Sen S, Sipahi S, et al. Regressive course of oxalate deposition in primary hyperoxaluria after kidney transplantation. Ren Fail. 2010;32(9):1131–6.CrossRef Celik G, Sen S, Sipahi S, et al. Regressive course of oxalate deposition in primary hyperoxaluria after kidney transplantation. Ren Fail. 2010;32(9):1131–6.CrossRef
11.
go back to reference Spasovski G, Beck BB, Blau N, et al. Late diagnosis of primary hyperoxaluria after failed kidney transplantation. Int Urol Nephrol. 2010;42(3):825–9.CrossRef Spasovski G, Beck BB, Blau N, et al. Late diagnosis of primary hyperoxaluria after failed kidney transplantation. Int Urol Nephrol. 2010;42(3):825–9.CrossRef
12.
go back to reference Malakoutian T, Asgari M, Houshmand M, et al. Recurrence of primary hyperoxaluria after kidney transplantation. Iran J Kidney Dis. 2011;5(6):429–33.PubMed Malakoutian T, Asgari M, Houshmand M, et al. Recurrence of primary hyperoxaluria after kidney transplantation. Iran J Kidney Dis. 2011;5(6):429–33.PubMed
13.
go back to reference Naderi G, Tabassomi F, Latif A, et al. Primary hyperoxaluria type 1 diagnosed after kidney transplantation: the importance of pre-transplantation metabolic screening in recurrent urolithiasis. Saudi J Kidney Dis Transpl. 2015;26(4):783–5.CrossRef Naderi G, Tabassomi F, Latif A, et al. Primary hyperoxaluria type 1 diagnosed after kidney transplantation: the importance of pre-transplantation metabolic screening in recurrent urolithiasis. Saudi J Kidney Dis Transpl. 2015;26(4):783–5.CrossRef
14.
go back to reference Rios JFN, Zuluaga M, Higuita LMS, et al. Primary hyperoxaluria diagnosed after kidney transplantation: report of 2 cases and literature review. J Bras Nefrol. 2017;39(4):462–6.CrossRef Rios JFN, Zuluaga M, Higuita LMS, et al. Primary hyperoxaluria diagnosed after kidney transplantation: report of 2 cases and literature review. J Bras Nefrol. 2017;39(4):462–6.CrossRef
15.
go back to reference Liu S, Gao B, Wang G, et al. Recurrent primary hyperoxaluria type 2 leads to early post-transplant renal function loss: a case report. Exp Ther Med. 2018;15(4):3169–72.PubMedPubMedCentral Liu S, Gao B, Wang G, et al. Recurrent primary hyperoxaluria type 2 leads to early post-transplant renal function loss: a case report. Exp Ther Med. 2018;15(4):3169–72.PubMedPubMedCentral
16.
go back to reference Bergstralh EJ, Monico CG, Lieske JC. Et al; IPHR investigators. Transplantation outcomes in primary Hyperoxaluria. Am J Transplant. 2010;10(11):2493–501.CrossRef Bergstralh EJ, Monico CG, Lieske JC. Et al; IPHR investigators. Transplantation outcomes in primary Hyperoxaluria. Am J Transplant. 2010;10(11):2493–501.CrossRef
17.
go back to reference Moray G, Tezcaner T, Özçay F, et al. Liver and kidney transplant in primary hyperoxaluria: a single center experience. Exp Clin Transplant. 2015;13(Suppl 1):145–7.PubMed Moray G, Tezcaner T, Özçay F, et al. Liver and kidney transplant in primary hyperoxaluria: a single center experience. Exp Clin Transplant. 2015;13(Suppl 1):145–7.PubMed
18.
go back to reference Compagnon P, Metzler P, Samuel D, et al. Long-term results of combined liver-kidney transplantation for primary Hyperoxaluria type 1: the French experience. Liver Transpl. 2014;20(12):1475–85.PubMed Compagnon P, Metzler P, Samuel D, et al. Long-term results of combined liver-kidney transplantation for primary Hyperoxaluria type 1: the French experience. Liver Transpl. 2014;20(12):1475–85.PubMed
19.
go back to reference Martin-Higueras C, Torres A, Salido E. Molecular therapy of primary hyperoxaluria. J Inherit Metab Dis. 2017;40(4):481–9.CrossRef Martin-Higueras C, Torres A, Salido E. Molecular therapy of primary hyperoxaluria. J Inherit Metab Dis. 2017;40(4):481–9.CrossRef
20.
go back to reference Roncador A, Oppici E, Talelli M, et al. Use of polymer conjugates for the intraperoxisomal delivery of engineered humanalanine: glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I. Nanomedicine. 2017;13(3):897–907.CrossRef Roncador A, Oppici E, Talelli M, et al. Use of polymer conjugates for the intraperoxisomal delivery of engineered humanalanine: glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I. Nanomedicine. 2017;13(3):897–907.CrossRef
21.
go back to reference Mesa-Torres N, Salido E, Pey AL. The lower limits for protein stability and foldability in primary hyperoxaluria type I. Biochim Biophys Acta. 2014;1844(12):2355–65.CrossRef Mesa-Torres N, Salido E, Pey AL. The lower limits for protein stability and foldability in primary hyperoxaluria type I. Biochim Biophys Acta. 2014;1844(12):2355–65.CrossRef
22.
go back to reference Frishberg Y, Zeharia A, Lyakhovetsky R, et al. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet. 2014;51(8):526–9.CrossRef Frishberg Y, Zeharia A, Lyakhovetsky R, et al. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet. 2014;51(8):526–9.CrossRef
23.
go back to reference Martin-Higueras C, Luis-Lima S, Salido E. Glycolate oxidase is safe and efficient target for substrate reduction therapy in a mouse model of primary Hyperoxaluria type I. Mol Ther. 2016;24(4):719–25.CrossRef Martin-Higueras C, Luis-Lima S, Salido E. Glycolate oxidase is safe and efficient target for substrate reduction therapy in a mouse model of primary Hyperoxaluria type I. Mol Ther. 2016;24(4):719–25.CrossRef
24.
go back to reference Dutta C, Avitahl-Curtis N, Pursell N, et al. Inhibition of Glycolate oxidase with dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary Hyperoxaluria type 1. Mol Ther. 2016;24(4):770–8.CrossRef Dutta C, Avitahl-Curtis N, Pursell N, et al. Inhibition of Glycolate oxidase with dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary Hyperoxaluria type 1. Mol Ther. 2016;24(4):770–8.CrossRef
25.
go back to reference Pey AL, Albert A, Salido E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. Biomed Res Int. 2013;2013:687658.CrossRef Pey AL, Albert A, Salido E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. Biomed Res Int. 2013;2013:687658.CrossRef
26.
go back to reference Oppici E, Fargue S, Reid ES, et al. Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine: glyoxylate aminotransferase causing primary hyperoxaluria type I. Hum Mol Genet. 2015;24(19):5500–11.CrossRef Oppici E, Fargue S, Reid ES, et al. Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine: glyoxylate aminotransferase causing primary hyperoxaluria type I. Hum Mol Genet. 2015;24(19):5500–11.CrossRef
27.
go back to reference Salido EC, Li XM, Lu Y, et al. Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci U S A. 2006;103(48):18249–54.CrossRef Salido EC, Li XM, Lu Y, et al. Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci U S A. 2006;103(48):18249–54.CrossRef
28.
go back to reference Salido E, Rodriguez-Pena M, Santana A, et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011;19(5):870–5.CrossRef Salido E, Rodriguez-Pena M, Santana A, et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011;19(5):870–5.CrossRef
29.
go back to reference Castello R, Borzone R, D'Aria S, et al. Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1. Gene Ther. 2016;23(2):129–34.CrossRef Castello R, Borzone R, D'Aria S, et al. Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1. Gene Ther. 2016;23(2):129–34.CrossRef
30.
go back to reference Kivelä JM, Räisänen-Sokolowski A, Pakarinen MP, et al. Long-term renal function in children after liver transplantation. Transplantation. 2011;91(1):115–20.CrossRef Kivelä JM, Räisänen-Sokolowski A, Pakarinen MP, et al. Long-term renal function in children after liver transplantation. Transplantation. 2011;91(1):115–20.CrossRef
31.
go back to reference Zapata-Linares N, Rodriguez S, Salido E, et al. Generation and characterization of human iPSC lines derived from a primary Hyperoxaluria type I patient with p. I244T mutation. Stem Cell Res. 2016;16(1):116–9.CrossRef Zapata-Linares N, Rodriguez S, Salido E, et al. Generation and characterization of human iPSC lines derived from a primary Hyperoxaluria type I patient with p. I244T mutation. Stem Cell Res. 2016;16(1):116–9.CrossRef
Metadata
Title
Primary hyperoxaluria diagnosed after kidney transplantation failure: lesson from 3 case reports and literature review
Authors
Ruiming Cai
Minzhuang Lin
Zhiyong Chen
Yongtong Lai
Xianen Huang
Guozhi Zhao
Xuekun Guo
Zhongtang Xiong
Juan Chen
Hui Chen
Qingping Jiang
Shaoyan Liu
Yuexin Yang
Weixiang Liang
Minhui Zou
Tao Liu
Wenfang Chen
Hongzhou Liu
Juan Peng
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1402-2

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.